MedPath

Yoga for lung functions in COVID-19 survivors

Phase 2
Conditions
Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Registration Number
CTRI/2021/09/036829
Lead Sponsor
All India Institute of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

a)Known case of COVID patients with respiratory symptoms on screening (RT-PCR negative or 4 weeks to 8 weeks from the onset of first symptom)

b)Patients with forced vital capacity(FVC) <80%

c)Patients of both sex and age of18-75years

d)Patients who are able and willing to practice any form of exercise when recruited under the study

e)Patients who are not engaged in regular and structured yoga practice.

Exclusion Criteria

a)Patients with forced vital capacity FVC <40 %

b)Previous pulmonary complications like severe asthma, COPD, bronchiectasis, interstitial lung disease(IL)

c)Known cases of CAD with moderate to severe LV dysfunction, patients with a history of CV or neurodegenerative diseases.

d)Lactating and pregnant women.

e)Patients currently participating in any other clinical trials with intervention.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Pulmonary Function: Diffusion lung capacity for carbon monoxide (DLCO), Forced Vital capacity (FVC), Forced expiratory volume in first second (FEV1), Total lung capacity (TLC) using Pulmonary function testTimepoint: Baseline, after 6 weeks and at the end of 12 weeks
Secondary Outcome Measures
NameTimeMethod
Severity of dyspnea using UCSD Shortness of Breath Questionnaire. <br/ ><br>Exercise capacity using 6-minute walk test <br/ ><br>Inflammatory markers such as Interleukin-6(IL-6) and C-reactive protein (CRP). <br/ ><br>Total severity score, presence of significant extension of fibrotic abnormalities, ground glass <br/ ><br>Opacities (GGO) and consolidation, lobar distribution and linear opacities using HRCT of lungs Psychological assessment using general Anxiety Disorder-7(GAD-7), Patient Health Questionaire9 (PHQ-9) <br/ ><br>Health related quality of life (QOL) using short form (SF-36)Timepoint: Baseline, after 6 weeks and at the end of 12 weeks
© Copyright 2025. All Rights Reserved by MedPath